跳至主要内容
临床试验/NCT07488624
NCT07488624已完成不适用

Development and Internal Validation of a Clinicopathologic Prognostic Model for Overall Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoimmunotherapy and Esophagectomy: A Multicenter Retrospective Cohort Study

Sichuan University3 个研究点 分布在 1 个国家目标入组 414 人开始时间: 2026年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
414
试验地点
3
主要终点
Overall Survival (OS)

研究概览

简要总结

The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy.

Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy

排除标准

  • •History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data

研究组 & 干预措施

ESCC Cohort After Neoadjuvant Chemoimmunotherapy and Esophagectomy

This cohort includes patients aged 18-80 years with histologically confirmed esophageal squamous cell carcinoma who received at least one cycle of neoadjuvant chemoimmunotherapy followed by esophagectomy. Patients were treated at three participating medical centers between 2019 and 2025.

结局指标

主要结局

Overall Survival (OS)

时间窗: From the date of esophagectomy to death or last follow-up, up to 73 months.

Overall survival is defined as the interval from the date of esophagectomy to death from any cause. Participants alive at last contact are censored on the date of last follow-up.

次要结局

未报告次要终点

研究者

发起方
Sichuan University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhen-Yu Ding

Professor

Sichuan University

研究点 (3)

Loading locations...

相似试验